Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$7.3 million.

  • Mereo BioPharma's Cash from Operations rose 279.29% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.7 million, marking a year-over-year decrease of 829.72%. This contributed to the annual value of -$32.8 million for FY2024, which is 5537.57% down from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma's Cash from Operations is -$7.3 million, which was up 279.29% from -$7.7 million recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma's Cash from Operations peaked at $2.7 million during Q3 2023, and registered a low of -$9.4 million during Q4 2024.
  • Its 3-year average for Cash from Operations is -$7.0 million, with a median of -$7.8 million in 2023.
  • The largest annual percentage gain for Mereo BioPharma's Cash from Operations in the last 5 years was 1359.21% (2024), contrasted with its biggest fall of 38277.55% (2024).
  • Over the past 3 years, Mereo BioPharma's Cash from Operations (Quarter) stood at -$6.8 million in 2023, then tumbled by 38.75% to -$9.4 million in 2024, then increased by 22.41% to -$7.3 million in 2025.
  • Its Cash from Operations stands at -$7.3 million for Q3 2025, versus -$7.7 million for Q2 2025 and -$8.3 million for Q1 2025.